AI drugs pass Phase I but crash in Phase II efficacy trials at a 60% rate. Your new JTBD is crossing this chasm.
The $150M Phase II JTBD Gap
AI drugs pass Phase I but crash in Phase II efficacy trials at a 60% rate. Your new JTBD is crossing this chasm.